Legal & General Group Plc Has $10.86 Million Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Legal & General Group Plc trimmed its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 139,010 shares of the company’s stock after selling 2,289 shares during the period. Legal & General Group Plc owned approximately 0.28% of Prestige Consumer Healthcare worth $10,855,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PBH. Allspring Global Investments Holdings LLC raised its holdings in shares of Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock valued at $126,274,000 after purchasing an additional 49,331 shares during the last quarter. Geode Capital Management LLC lifted its position in Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after buying an additional 21,951 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Prestige Consumer Healthcare by 2.4% during the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after buying an additional 24,392 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of Prestige Consumer Healthcare by 5.0% in the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock valued at $70,964,000 after acquiring an additional 43,619 shares in the last quarter. Finally, Boston Trust Walden Corp increased its position in shares of Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after acquiring an additional 252,089 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.3 %

Shares of NYSE:PBH opened at $79.88 on Thursday. The stock has a market cap of $3.96 billion, a PE ratio of 18.71, a P/E/G ratio of 2.69 and a beta of 0.47. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The business has a 50 day moving average of $84.42 and a 200-day moving average of $79.97.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PBH shares. DA Davidson raised their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Canaccord Genuity Group lifted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.